Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27706710 | 0.84 | EGFR (0.49) | EGFRCSF1R | |
| SCHEMBL27576218 | 0.84 | EGFR (0.49) | EGFRCSF1R | |
| SCHEMBL29133739 | 0.70 | HTT (0.50) | — | |
| SCHEMBL29133745 | 0.70 | HTT (0.50) | — | |
| SCHEMBL29133752 | 0.69 | HTT (0.36) | EGFR | |
| SCHEMBL29133735 | 0.69 | HTT (0.36) | EGFR | |
| SCHEMBL16376054 | 0.68 | EGFR (0.72) | EGFRCSF1R | |
| SCHEMBL7496111 | 0.67 | TTBK1 (0.55) | EGFR | |
| SCHEMBL29133728 | 0.67 | IRAK4 (0.48) | EGFR | |
| Bromide SCHEMBL7497320 | 0.66 | TTBK1 (0.54) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100506224-C | Combinations comprising a selective cyclooxygenase-2 inhibitor | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| CN-1575168-A | Combinations comprising selective cyclooxygenase-2 inhibitors | NOVARTIS AG (CH) | 2005-02-02 | — | — | CN | disclosed |